High Power Electric Propulsion: MARS plus EUROPA – Already Beyond 2025!

It’s mid-term realization plus global strategic investments: the results of the European Russian DEMOCRITOS project (Horizon 2020) related to the MW class INPPS (International Nuclear Power and Propulsion System) flagship will be described. INPPS flagship includes high power electric thrusters cluster, supplied electric power by the nuclear reactor (successfully tested in Russia) and a solar power ring. Two INPPS versions were studied – the wide and arrow wing versions. Both versions have a futuristic design with standardized interfaces for several flagship subsystems. Especially the high payload mass of INPPS allows the transport of – for example – up to 12 t to JUPITER moon EUROPA and about 18 t to MARS – as a function of specific impulse of electric thrusters. INPPS flagship not only allows scientific, but especially commercial and communication payloads as well. This means industrial-scale production of space flight systems for robotic and human space exploration. International cooperation related to INPPS realization are necessary within an International High Power Space Transportation program to realize the DEMOCRITOS core, ground and space components until 2025. DEMOCRITOS project included partners from Europe, Russia and a Brazilian guest observer and received several inputs from NASA Cleveland and JAXA Tokyo

Non-Human + Human Deep Space Exploration: By The NEP INPPS Flagship

INPPS Flagship Structure & Subsystems, Ground Based Tests, Pure NEP, International Electric Thrusters, Humans Internationally To Mar

Mars- plus Europa-INPPS Flagship Missions with High Power Electric Thrusters and Heavy Science Payload

2020/2021 orbit calculations (DLR Bremen + MAI Moscow): 3 Orbits for one non-human MARS/EUROPA-INPPS flagship 1. Orbit Earth (11 Oct 2026) => Mars (28 Jan 2028); 2. Orbit Mars (22 Sept 2028) => Earth (29 Jul 2029); 3. Orbit Earth (12 Oct 2031) => Jupiter / Europa (6 Dec 2035) 22 ETs (for the INPPS flagship CET): example - gridded CET plate with combined ET

Humans to Mars: by MARS- plus EUROPA-INPPS Flagship Mission

The first non-human INPPS (International Nuclear Power and Propulsion System) flagship flight with orbits Earth-Mars-Earth-Jupiter/Europa (after 2025) is the most maximal space qualification test of INPPS flagship to carry out the second INPPS flagship flight to Mars with humans (in the 2030th). This high power space transportation tug is realistic because of A) the successful finalization of the European-Russian DEMOCRITOS and MEGAHIT projects with their three concepts of space, ground and nuclear demonstrators for INPPS realization (reached in 2017), B) the successful ground based test of the Russian nuclear reactor with 1MWel plus important heat dissipation solution via droplet radiators (confirmed in 2018), C) the space qualification of the Russian reactor by 2025 and D) the perfect celestial constellation for a Earth-Mars/Phobos-Earth-Jupiter/Europa trajectory between 2026 and 2035. Therefore the talk sketches the preparation status of INPPS flagship with its subsystems. Critical performance will be studied by parallel realizations of the ground and nuclear demonstrators of DEMOCRITOS (until 2025). The space qualification of INPPS with all subsystems including the nuclear reactor in the middle of the 2020th plus the INPPS tests for about one to two years - first in high Earth orbit robotic assembly phase of INPPS and later extended in nearby Earth space environment flight - means a complete concepts driven approval for all applied INPPS space subsystem technologies. It is also important to consider wider aspects for the overall mission implementation phase. Component like the nuclear reactor as the power source for the propulsion system will have to agree with the 1992 UN principles relevant to the use of nuclear power sources (NPS) in outer space. Therefore this talk will look into the legal and policy issues of nuclear space systems related to the international realization of mission design, requirements of associated safety regulations (including AI applications in the subsystems) and new aspects for INPPS flagship commercialization and new media communication on board

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

BACKGROUN

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin- kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent revascularization, or cardiovascular death; 93% of the patients were receiving statin therapy at baseline. The trials were stopped early after the sponsor elected to discontinue the development of bococizumab owing in part to the development of high rates of antidrug antibodies, as seen in data from other studies in the program. The median follow-up was 10 months. RESULTS At 14 weeks, patients in the combined trials had a mean change from baseline in LDL cholesterol levels of -56.0% in the bococizumab group and +2.9% in the placebo group, for a between-group difference of -59.0 percentage points (P<0.001) and a median reduction from baseline of 64.2% (P<0.001). In the lower-risk, shorter-duration trial (in which the patients had a baseline LDL cholesterol level of ≥70 mg per deciliter [1.8 mmol per liter] and the median follow-up was 7 months), major cardiovascular events occurred in 173 patients each in the bococizumab group and the placebo group (hazard ratio, 0.99; 95% confidence interval [CI], 0.80 to 1.22; P = 0.94). In the higher-risk, longer-duration trial (in which the patients had a baseline LDL cholesterol level of ≥100 mg per deciliter [2.6 mmol per liter] and the median follow-up was 12 months), major cardiovascular events occurred in 179 and 224 patients, respectively (hazard ratio, 0.79; 95% CI, 0.65 to 0.97; P = 0.02). The hazard ratio for the primary end point in the combined trials was 0.88 (95% CI, 0.76 to 1.02; P = 0.08). Injection-site reactions were more common in the bococizumab group than in the placebo group (10.4% vs. 1.3%, P<0.001). CONCLUSIONS In two randomized trials comparing the PCSK9 inhibitor bococizumab with placebo, bococizumab had no benefit with respect to major adverse cardiovascular events in the trial involving lower-risk patients but did have a significant benefit in the trial involving higher-risk patients